menu search

SPRY / Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday

Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday
ARS Pharmaceutical is seeking the approval of Neffy, a nasal spray version of epinephrine. The FDA is seeking additional dosing studies before approving Neffy. Read More
Posted: Sep 20 2023, 12:42
Author Name: The Motley Fool
Views: 112571

SPRY News  

Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday

By The Motley Fool
September 20, 2023

Why Shares of ARS Pharmaceuticals Are Plummeting on Wednesday

ARS Pharmaceutical is seeking the approval of Neffy, a nasal spray version of epinephrine. The FDA is seeking additional dosing studies before approvi more_horizontal

ARS Pharmaceuticals stock falls toward record selloff after FDA issues surprise CRL, requesting additional studies

By Market Watch
September 20, 2023

ARS Pharmaceuticals stock falls toward record selloff after FDA issues surprise CRL, requesting additional studies

Sharesof ARS Pharmaceuticals Inc. SPRY plunged 46.9% toward a 15-month low in premarket trading Wednesday, after the biopharmaceutical company said th more_horizontal

ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray

By Zacks Investment Research
May 15, 2023

ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray

ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions. more_horizontal


Search within

Pages Search Results: